- Availability of Non-calcium, Non-resin FOSRENOL Gives New Therapy Choice for the Management of Hyperphosphataemia in End-Stage Renal Disease Patients(1) in Japan Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announces the Japanese launch of FOSRENOL(R) (lanthanum carbonate), which is now available to prescribers and patients in Japan through Shire's strategic alliance partner Bayer Yakuhin Ltd. FOSRENOL is the first commercially available non